aspirin has been researched along with Carcinoma, Anaplastic in 45 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although aspirin is recommended for the prevention of colorectal cancer, the specific individuals for whom the benefits outweigh the risks are not clearly defined." | 9.24 | ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. ( Backman, V; Carolan, PJ; Chan, AT; Chin, SM; Chung, DC; Colizzo, FP; Drew, DA; Flagg, M; Freedman, M; Gala, M; Garber, JJ; Gilpin, KK; Huttenhower, C; Kedrin, D; Khalili, H; Kwon, DS; Markowitz, SD; Milne, GL; Nishioka, NS; Parziale, M; Pond, E; Rawlings, CA; Richter, JM; Roy, HK; Schuck, MM; Staller, K; Stewart, K; Wang, M, 2017) |
| "To assess the efficacy of fertility-sparing treatment using medroxyprogesterone acetate (MPA) for endometrial carcinoma (EC) and atypical endometrial hyperplasia (AH) in young women." | 9.12 | Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. ( Fukunaga, M; Hatae, M; Hiura, M; Iwasaka, T; Kamura, T; Kodama, S; Konishi, I; Nakanishi, T; Saito, T; Saji, F; Sakamoto, A; Sasaki, H; Terakawa, N; Tsuda, H; Ushijima, K; Yaegashi, N; Yahata, H; Yasugi, T; Yoshikawa, H, 2007) |
| "Aspirin was administered at a dose of 81 mg once daily for 28 days in a cohort of 92 matched high-risk and normal-risk colorectal cancer subjects." | 9.09 | Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. ( Bailey, J; Boland, CR; Brenner, DE; Burney, K; Krishnan, K; Normolle, D; Peters-Golden, M; Rock, CL; Ruffin, MT; Shureiqi, I, 2001) |
| "In this study, we observed that low-dose aspirin use was associated with a lower risk of lung carcinoma and lung carcinoma-related mortality among COPD patients." | 8.12 | Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong: A cohort study. ( Cheung, KS; Ip, MS; Li, HL; Li, X; Ren, QW; Tse, HF; Wong, PF; Wu, MZ; Yiu, KH; Yu, SY, 2022) |
| " We aimed to examine aspirin use on cancer-specific survival in various BTC subtypes, including gallbladder cancer, ampulla of Vater cancer, and cholangiocarcinoma." | 8.02 | Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer-Specific Mortality in a Large Nationwide Cohort. ( Chan, C; Chen, CJ; Chen, YJ; Hsieh, RJ; Huang, C; Huang, CP; Huang, YH; Jackson, SS; Koshiol, J; Lee, MH; Liao, SF; Liu, PC; Lu, SN; Shen, CY, 2021) |
| "Aspirin is associated with a reduced risk of developing colorectal cancer." | 7.79 | Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. ( Donnan, PT; McCowan, C; Munro, AJ; Steele, RJ, 2013) |
| "Regular aspirin intake is associated with a reduction in the incidence of colorectal cancer." | 7.76 | Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line. ( Brown, JE; Dibra, HK; Hooley, P; Nicholl, ID, 2010) |
| "Regular aspirin intake may reduce the risk of colorectal cancer by 50%." | 7.69 | Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines. ( Elder, DJ; Hague, A; Hicks, DJ; Paraskeva, C, 1996) |
| "Nine trials with 150 familial adenomatous polyposis (FAP) and 24,143 population subjects met the inclusion criteria." | 6.42 | Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. ( Asano, TK; McLeod, RS, 2004) |
| "A total of 5308 patients with type 2 diabetes were identified by the National Health Insurance from 1998 to 2000 and followed up until 2013." | 5.72 | Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study. ( Hsu, WH; Huang, HY; Lee, MY; Liang, HL; Lu, TW; Sung, YW, 2022) |
| "Although aspirin is recommended for the prevention of colorectal cancer, the specific individuals for whom the benefits outweigh the risks are not clearly defined." | 5.24 | ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. ( Backman, V; Carolan, PJ; Chan, AT; Chin, SM; Chung, DC; Colizzo, FP; Drew, DA; Flagg, M; Freedman, M; Gala, M; Garber, JJ; Gilpin, KK; Huttenhower, C; Kedrin, D; Khalili, H; Kwon, DS; Markowitz, SD; Milne, GL; Nishioka, NS; Parziale, M; Pond, E; Rawlings, CA; Richter, JM; Roy, HK; Schuck, MM; Staller, K; Stewart, K; Wang, M, 2017) |
| "In a randomized, placebo-controlled trial, we used a two-by-two design to investigate the effects of aspirin, at a dose of 600 mg per day, and resistant starch (Novelose), at a dose of 30 g per day, in reducing the risk of adenoma and carcinoma among persons with the Lynch syndrome." | 5.13 | Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. ( Barker, G; Bertario, L; Bisgaard, ML; Bishop, DT; Burn, J; Dunlop, M; Eccles, D; Elliott, F; Evans, DG; Fodde, R; Ho, JW; Jarvinen, HJ; Jass, JR; Lindblom, A; Lubinski, J; Lynch, HT; Macrae, F; Maher, ER; Mathers, JC; Mecklin, JP; Morrison, PJ; Möslein, G; Olschwang, S; Ramesar, R; Scott, RJ; Side, L; Thomas, HJ; Vasen, HF, 2008) |
| "To assess the efficacy of fertility-sparing treatment using medroxyprogesterone acetate (MPA) for endometrial carcinoma (EC) and atypical endometrial hyperplasia (AH) in young women." | 5.12 | Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. ( Fukunaga, M; Hatae, M; Hiura, M; Iwasaka, T; Kamura, T; Kodama, S; Konishi, I; Nakanishi, T; Saito, T; Saji, F; Sakamoto, A; Sasaki, H; Terakawa, N; Tsuda, H; Ushijima, K; Yaegashi, N; Yahata, H; Yasugi, T; Yoshikawa, H, 2007) |
| "Aspirin was administered at a dose of 81 mg once daily for 28 days in a cohort of 92 matched high-risk and normal-risk colorectal cancer subjects." | 5.09 | Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. ( Bailey, J; Boland, CR; Brenner, DE; Burney, K; Krishnan, K; Normolle, D; Peters-Golden, M; Rock, CL; Ruffin, MT; Shureiqi, I, 2001) |
| " Baseline or on-study aspirin use was associated with modest increases in grade 3 and 4 bleeding events in both treatment groups, from 3." | 4.84 | Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. ( Bergsland, E; Gerber, HP; Holden, SN; Holmgren, E; Hurwitz, H; Kabbinavar, F; Miller, K; Ngai, J; Scappaticci, FA; Skillings, JR; Wang, J, 2007) |
| "In this study, we observed that low-dose aspirin use was associated with a lower risk of lung carcinoma and lung carcinoma-related mortality among COPD patients." | 4.12 | Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong: A cohort study. ( Cheung, KS; Ip, MS; Li, HL; Li, X; Ren, QW; Tse, HF; Wong, PF; Wu, MZ; Yiu, KH; Yu, SY, 2022) |
| " We aimed to examine aspirin use on cancer-specific survival in various BTC subtypes, including gallbladder cancer, ampulla of Vater cancer, and cholangiocarcinoma." | 4.02 | Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer-Specific Mortality in a Large Nationwide Cohort. ( Chan, C; Chen, CJ; Chen, YJ; Hsieh, RJ; Huang, C; Huang, CP; Huang, YH; Jackson, SS; Koshiol, J; Lee, MH; Liao, SF; Liu, PC; Lu, SN; Shen, CY, 2021) |
| "Regular aspirin use has been associated to decreased risk of several cancers, but evidence on nasopharyngeal carcinoma is scanty." | 3.81 | Regular aspirin use and nasopharyngeal cancer risk: A case-control study in Italy. ( Bosetti, C; Di Maso, M; Garavello, W; La Vecchia, C; Libra, M; Montella, M; Polesel, J; Serraino, D, 2015) |
| "Aspirin is associated with a reduced risk of developing colorectal cancer." | 3.79 | Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. ( Donnan, PT; McCowan, C; Munro, AJ; Steele, RJ, 2013) |
| "Regular aspirin intake is associated with a reduction in the incidence of colorectal cancer." | 3.76 | Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line. ( Brown, JE; Dibra, HK; Hooley, P; Nicholl, ID, 2010) |
| "The association between lung carcinoma risk and regular use of NSAIDs, including aspirin, was evaluated in a hospital-based case-control study of 1038 patients and 1002 controls." | 3.72 | Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. ( Altorki, NK; Chen, SQ; Citron, M; Muscat, JE; Neugut, AI; Olson, S; Richie, JP; Stellman, SD, 2003) |
| "Regular aspirin intake may reduce the risk of colorectal cancer by 50%." | 3.69 | Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines. ( Elder, DJ; Hague, A; Hicks, DJ; Paraskeva, C, 1996) |
| " There is substantial evidence that N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) is deformylated to 2-amino-4-(5-nitro-2-furyl)thiazole (ANFT) in the process of FANFT-induced bladder cancer." | 3.67 | Role of renal metabolism and excretion in 5-nitrofuran-induced uroepithelial cancer in the rat. ( Cohen, SM; Davis, BB; Spry, LA; Zenser, TV, 1985) |
| " The effects of warfarin, aspirin and heparin administration on the early arrest patterns of 125IdUrd-labelled TA3 carcinoma and Gardner lymphosarcoma cells injected intravenously into tumor-bearing mice were examined." | 3.66 | Initial tumor cell arrest in animals of defined coagulative status. ( Glaves, D; Weiss, L, 1978) |
| "Lynch syndrome is an autosomal-dominant hereditary cancer syndrome." | 2.55 | Approach to Lynch Syndrome for the Gastroenterologist. ( Bui, QM; Ho, W; Lin, D, 2017) |
| "Nine trials with 150 familial adenomatous polyposis (FAP) and 24,143 population subjects met the inclusion criteria." | 2.42 | Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. ( Asano, TK; McLeod, RS, 2004) |
| "A total of 5308 patients with type 2 diabetes were identified by the National Health Insurance from 1998 to 2000 and followed up until 2013." | 1.72 | Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study. ( Hsu, WH; Huang, HY; Lee, MY; Liang, HL; Lu, TW; Sung, YW, 2022) |
| "Risk models for advanced colorectal neoplasms generally yielded modest discriminatory power, despite some variation in performance between models." | 1.51 | Head-to-Head Comparison of the Performance of 17 Risk Models for Predicting Presence of Advanced Neoplasms in Colorectal Cancer Screening. ( Balavarca, Y; Brenner, H; Hoffmeister, M; Peng, L; Weigl, K, 2019) |
| "Previous studies have suggested that migraineurs are at decreased risk for developing breast cancer." | 1.39 | Migraine and subsequent risk of breast cancer: a prospective cohort study. ( Buring, JE; Kurth, T; Lee, IM; Rexrode, KM; Tamimi, RM; Winter, AC, 2013) |
| "The risk of postoperative hemorrhage following gastric ESD was higher in patients with antithrombotic therapy than in those without that therapy." | 1.39 | The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection. ( Edogawa, S; Harada, S; Higuchi, K; Kojima, Y; Ota, K; Takeuchi, T; Tokioka, S; Umegaki, E, 2013) |
| "In support of this, the breast cancer cell line MCF-7 stimulated secretion of VEGF and a pro-angiogenic releasate from platelets." | 1.37 | Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. ( Battinelli, EM; Italiano, JE; Markens, BA, 2011) |
| " We investigated the long-term administration of low dose of aspirin in a model of experimental colon carcinogenesis in rats." | 1.36 | Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis. ( Bouhadjar, M; Bousserouel, S; Gosse, F; Marescaux, J; Raul, F; Soler, L, 2010) |
| "Diclofenac was COX-1/2 non-selective when tested in vitro, but a slightly preferential inhibitor of COX-2 when tested ex vivo." | 1.30 | Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. ( Giuliano, F; Warner, TD, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (15.56) | 18.7374 |
| 1990's | 3 (6.67) | 18.2507 |
| 2000's | 11 (24.44) | 29.6817 |
| 2010's | 19 (42.22) | 24.3611 |
| 2020's | 5 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, SY | 1 |
| Ip, MS | 1 |
| Li, X | 1 |
| Cheung, KS | 1 |
| Ren, QW | 1 |
| Wu, MZ | 1 |
| Li, HL | 1 |
| Wong, PF | 1 |
| Tse, HF | 1 |
| Yiu, KH | 1 |
| Zaccari, P | 1 |
| Archibugi, L | 1 |
| Belfiori, G | 1 |
| Nista, E | 1 |
| dell'Anna, G | 1 |
| Crippa, S | 1 |
| Schepis, T | 1 |
| Tacelli, M | 1 |
| Aleotti, F | 1 |
| Petrone, MC | 1 |
| Mariani, A | 1 |
| Costamagna, G | 1 |
| Gasbarrini, A | 1 |
| Larghi, A | 1 |
| Falconi, M | 1 |
| Arcidiacono, PG | 1 |
| Capurso, G | 1 |
| Huang, HY | 1 |
| Lu, TW | 1 |
| Liang, HL | 1 |
| Hsu, WH | 1 |
| Sung, YW | 1 |
| Lee, MY | 1 |
| Peng, L | 1 |
| Balavarca, Y | 1 |
| Weigl, K | 1 |
| Hoffmeister, M | 1 |
| Brenner, H | 1 |
| Liao, SF | 1 |
| Koshiol, J | 1 |
| Huang, YH | 2 |
| Jackson, SS | 1 |
| Chan, C | 1 |
| Huang, C | 1 |
| Liu, PC | 1 |
| Chen, YJ | 1 |
| Hsieh, RJ | 1 |
| Huang, CP | 1 |
| Lu, SN | 1 |
| Chen, CJ | 1 |
| Shen, CY | 1 |
| Lee, MH | 1 |
| Kamal, H | 1 |
| Sadr-Azodi, O | 1 |
| Engstrand, L | 1 |
| Brusselaers, N | 1 |
| Sahin, IH | 1 |
| McCowan, C | 2 |
| Donnan, PT | 2 |
| Munro, AJ | 2 |
| Steele, RJ | 2 |
| Takeuchi, T | 1 |
| Ota, K | 1 |
| Harada, S | 1 |
| Edogawa, S | 1 |
| Kojima, Y | 1 |
| Tokioka, S | 1 |
| Umegaki, E | 1 |
| Higuchi, K | 1 |
| Di Maso, M | 1 |
| Bosetti, C | 1 |
| La Vecchia, C | 1 |
| Garavello, W | 1 |
| Montella, M | 1 |
| Libra, M | 1 |
| Serraino, D | 1 |
| Polesel, J | 1 |
| Sanin, V | 1 |
| Pfetsch, V | 1 |
| Koenig, W | 1 |
| Bui, QM | 1 |
| Lin, D | 1 |
| Ho, W | 1 |
| Drew, DA | 1 |
| Chin, SM | 1 |
| Gilpin, KK | 1 |
| Parziale, M | 1 |
| Pond, E | 1 |
| Schuck, MM | 1 |
| Stewart, K | 1 |
| Flagg, M | 1 |
| Rawlings, CA | 1 |
| Backman, V | 1 |
| Carolan, PJ | 1 |
| Chung, DC | 1 |
| Colizzo, FP | 1 |
| Freedman, M | 1 |
| Gala, M | 1 |
| Garber, JJ | 1 |
| Huttenhower, C | 1 |
| Kedrin, D | 1 |
| Khalili, H | 1 |
| Kwon, DS | 1 |
| Markowitz, SD | 1 |
| Milne, GL | 1 |
| Nishioka, NS | 1 |
| Richter, JM | 1 |
| Roy, HK | 1 |
| Staller, K | 1 |
| Wang, M | 1 |
| Chan, AT | 1 |
| Parmar, HS | 1 |
| Houdek, Z | 1 |
| Pesta, M | 1 |
| Vaclava, C | 1 |
| Dvorak, P | 1 |
| Hatina, J | 1 |
| Burn, J | 1 |
| Bishop, DT | 1 |
| Mecklin, JP | 1 |
| Macrae, F | 1 |
| Möslein, G | 1 |
| Olschwang, S | 1 |
| Bisgaard, ML | 1 |
| Ramesar, R | 1 |
| Eccles, D | 1 |
| Maher, ER | 1 |
| Bertario, L | 1 |
| Jarvinen, HJ | 1 |
| Lindblom, A | 1 |
| Evans, DG | 1 |
| Lubinski, J | 1 |
| Morrison, PJ | 1 |
| Ho, JW | 1 |
| Vasen, HF | 1 |
| Side, L | 1 |
| Thomas, HJ | 1 |
| Scott, RJ | 1 |
| Dunlop, M | 1 |
| Barker, G | 1 |
| Elliott, F | 1 |
| Jass, JR | 1 |
| Fodde, R | 1 |
| Lynch, HT | 1 |
| Mathers, JC | 1 |
| Zell, JA | 1 |
| Ziogas, A | 1 |
| Bernstein, L | 1 |
| Clarke, CA | 1 |
| Deapen, D | 1 |
| Largent, JA | 1 |
| Neuhausen, SL | 1 |
| Stram, DO | 1 |
| Ursin, G | 1 |
| Anton-Culver, H | 1 |
| Bousserouel, S | 1 |
| Gosse, F | 1 |
| Bouhadjar, M | 1 |
| Soler, L | 1 |
| Marescaux, J | 1 |
| Raul, F | 1 |
| Vieth, M | 1 |
| Görgens, D | 1 |
| Langner, C | 1 |
| Dibra, HK | 1 |
| Brown, JE | 1 |
| Hooley, P | 1 |
| Nicholl, ID | 1 |
| Brasky, TM | 1 |
| Bonner, MR | 1 |
| Moysich, KB | 1 |
| Ambrosone, CB | 1 |
| Nie, J | 1 |
| Tao, MH | 1 |
| Edge, SB | 1 |
| Kallakury, BV | 1 |
| Marian, C | 1 |
| Goerlitz, DS | 1 |
| Trevisan, M | 1 |
| Shields, PG | 1 |
| Freudenheim, JL | 1 |
| Battinelli, EM | 1 |
| Markens, BA | 1 |
| Italiano, JE | 1 |
| Cheng, BQ | 1 |
| Jiang, Y | 1 |
| Li, DL | 1 |
| Fan, JJ | 1 |
| Ma, M | 1 |
| Winter, AC | 1 |
| Rexrode, KM | 1 |
| Lee, IM | 1 |
| Buring, JE | 1 |
| Tamimi, RM | 1 |
| Kurth, T | 1 |
| Printz, C | 1 |
| Serebruany, VL | 1 |
| Dinicolantonio, JJ | 1 |
| Can, MM | 1 |
| Goto, S | 1 |
| Muscat, JE | 1 |
| Chen, SQ | 1 |
| Richie, JP | 1 |
| Altorki, NK | 1 |
| Citron, M | 1 |
| Olson, S | 1 |
| Neugut, AI | 1 |
| Stellman, SD | 1 |
| KINLOCH, JD | 1 |
| WEBB, JN | 1 |
| ECCLESTON, D | 1 |
| ZEITLIN, J | 1 |
| Asano, TK | 1 |
| McLeod, RS | 1 |
| Raskov, HH | 1 |
| Fisher, GH | 1 |
| Geronemus, RG | 1 |
| Ushijima, K | 1 |
| Yahata, H | 1 |
| Yoshikawa, H | 1 |
| Konishi, I | 1 |
| Yasugi, T | 1 |
| Saito, T | 2 |
| Nakanishi, T | 1 |
| Sasaki, H | 1 |
| Saji, F | 1 |
| Iwasaka, T | 1 |
| Hatae, M | 1 |
| Kodama, S | 1 |
| Terakawa, N | 1 |
| Yaegashi, N | 1 |
| Hiura, M | 1 |
| Sakamoto, A | 1 |
| Tsuda, H | 1 |
| Fukunaga, M | 1 |
| Kamura, T | 1 |
| Scappaticci, FA | 1 |
| Skillings, JR | 1 |
| Holden, SN | 1 |
| Gerber, HP | 1 |
| Miller, K | 1 |
| Kabbinavar, F | 1 |
| Bergsland, E | 1 |
| Ngai, J | 1 |
| Holmgren, E | 1 |
| Wang, J | 1 |
| Hurwitz, H | 1 |
| Xin, B | 1 |
| Yokoyama, Y | 1 |
| Shigeto, T | 1 |
| Mizunuma, H | 1 |
| Sweeting, JG | 1 |
| Elder, DJ | 1 |
| Hague, A | 1 |
| Hicks, DJ | 1 |
| Paraskeva, C | 1 |
| Giuliano, F | 1 |
| Warner, TD | 1 |
| Krishnan, K | 1 |
| Ruffin, MT | 1 |
| Normolle, D | 1 |
| Shureiqi, I | 1 |
| Burney, K | 1 |
| Bailey, J | 1 |
| Peters-Golden, M | 1 |
| Rock, CL | 1 |
| Boland, CR | 1 |
| Brenner, DE | 1 |
| Flescher, E | 1 |
| Rotem, R | 1 |
| Glaves, D | 1 |
| Weiss, L | 1 |
| Spry, LA | 1 |
| Zenser, TV | 1 |
| Cohen, SM | 1 |
| Davis, BB | 1 |
| Jaffe, BM | 1 |
| Hegarty, MM | 1 |
| Grime, RT | 1 |
| Schofield, PF | 1 |
| Gasic, GJ | 1 |
| Gasic, TB | 1 |
| Galanti, N | 1 |
| Johnson, T | 1 |
| Murphy, S | 1 |
| Moertel, CG | 1 |
| Ahmann, DL | 1 |
| Taylor, WF | 1 |
| Schwartau, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ASPIRED: ASPirin Intervention for the REDuction of Colorectal Cancer Risk[NCT02394769] | 180 participants (Actual) | Interventional | 2015-07-06 | Active, not recruiting | |||
| Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma[NCT03463252] | Phase 2/Phase 3 | 224 participants (Anticipated) | Interventional | 2018-04-01 | Recruiting | ||
| A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF (Bevacizumab), in Combination With Capecitabine Chemotherapy, in Subjects With Previously Treated Metastatic Bre[NCT00109239] | Phase 3 | 0 participants | Interventional | 2000-11-30 | Completed | ||
| A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard Chemotherapy in Subjects With Metastatic Colorectal Cancer[NCT00109070] | Phase 3 | 0 participants | Interventional | 2000-09-30 | Completed | ||
| A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab), a Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, in Combination With 5-[NCT00109226] | Phase 2 | 0 participants | Interventional | 2000-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measured using liquid chromatography/mass spectrometry (NCT02394769)
Timeframe: 8-12 weeks
| Intervention | ng/mg cr (Mean) | ||
|---|---|---|---|
| Baseline urinary PGE-M | Post-intervention urinary PGE-M | Change in urinary PGE-M | |
| Low Dose Aspirin | 17.7 | 13.1 | -4.6 |
| Placebo (For Aspirin) | 15.5 | 16.4 | 0.8 |
| Standard Dose Aspirin | 14.3 | 9.4 | -4.9 |
6 reviews available for aspirin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
[ASA - from cardiovascular to cancer prevention].
Topics: Aspirin; Carcinoma; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Male; Proton | 2016 |
Approach to Lynch Syndrome for the Gastroenterologist.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Colectomy; Colonoscopy; Colore | 2017 |
Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas.
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Co | 2004 |
[Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2006 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Prostaglandins and cancer: an update.
Topics: Animals; Aspirin; Bucladesine; Calcium; Carcinoma; Cell Division; Cell Line; Depression, Chemical; H | 1974 |
5 trials available for aspirin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.
Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Aspirin; Biomarkers, T | 2017 |
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.
Topics: Adenoma; Adult; Aged; Aspirin; Carcinoma; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Non | 2008 |
Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.
Topics: Adult; Aspirin; Carcinoma; Disease-Free Survival; Endometrial Neoplasms; Endometrium; Female; Fertil | 2007 |
Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Aspirin; Biomarkers, Tumor; Biopsy, Needle; Carcinoma; Colorectal | 2001 |
Aspirin and pancreatic cancer pain.
Topics: Adenocarcinoma; Aspirin; Carcinoma; Codeine; Colonic Neoplasms; Humans; Pancreatic Neoplasms; Placeb | 1971 |
34 other studies available for aspirin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong: A cohort study.
Topics: Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Cohor | 2022 |
Risk factors for the occurrence of ampullary tumors: A case-control study.
Topics: Adenoma; Ampulla of Vater; Aspirin; Carcinoma; Case-Control Studies; Common Bile Duct Neoplasms; Duo | 2022 |
Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study.
Topics: Aspirin; Carcinoma; Diabetes Mellitus, Type 2; Dipyridamole; Humans; Liver Neoplasms; Platelet Aggre | 2022 |
Head-to-Head Comparison of the Performance of 17 Risk Models for Predicting Presence of Advanced Neoplasms in Colorectal Cancer Screening.
Topics: Adenoma; Age Factors; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Area Under Cu | 2019 |
Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer-Specific Mortality in a Large Nationwide Cohort.
Topics: Aged; Aged, 80 and over; Ampulla of Vater; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Du | 2021 |
Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Duct Neoplasms; Bile | 2021 |
The impact of aspirin use on colorectal cancer patients.
Topics: Aspirin; Carcinoma; Colorectal Neoplasms; Female; Humans; Male | 2013 |
Response to letter commenting on paper EJC-D-12-01401: Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality.
Topics: Aspirin; Carcinoma; Colorectal Neoplasms; Female; Humans; Male | 2013 |
The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection.
Topics: Adenoma; Aged; Anti-Ulcer Agents; Anticoagulants; Aspirin; Carcinoma; Case-Control Studies; Clopidog | 2013 |
Regular aspirin use and nasopharyngeal cancer risk: A case-control study in Italy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Case-Control Studies; Fema | 2015 |
Protective Effect of Aspirin Against Oligomeric Aβ42 Induced Mitochondrial Alterations and Neurotoxicity in Differentiated EC P19 Neuronal Cells.
Topics: Amyloid beta-Peptides; Analysis of Variance; Animals; Apoptosis; Aspirin; Carcinoma; Cell Differenti | 2017 |
Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Colorectal Neoplasms; Female; Fol | 2009 |
Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Azoxymethane; Carc | 2010 |
[Pseudoneoplastic regeneration of the stomach. Histopathology and differential diagnosis].
Topics: Aspirin; Carcinoma; Diagnosis, Differential; Gastritis; Helicobacter Infections; Humans; Intestinal | 2010 |
Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Cell Line, Tumor; Cell Survival; Colore | 2010 |
Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers, Tumor; Breast Neoplasms; | 2011 |
Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis.
Topics: Adenosine Diphosphate; Angiogenesis Modulating Agents; Aspirin; Blood Platelets; Breast Neoplasms; C | 2011 |
Up-regulation of thy-1 promotes invasion and metastasis of hepatocarcinomas.
Topics: alpha-Fetoproteins; Analysis of Variance; Aspirin; Cadherins; Carcinoma; Cell Differentiation; Chi-S | 2012 |
Migraine and subsequent risk of breast cancer: a prospective cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Breast Neoplasms; Carcinoma; Chemoprevention; Cohort Studies; Doub | 2013 |
Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Cause o | 2013 |
Aspirin extends life of some patients with colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Class I Phosphatidylinositol 3-Kinases; | 2013 |
Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel.
Topics: Aged; Aspirin; Brain Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Clopidogrel; Colonic | 2013 |
Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Case-Control Studies; Female; Hum | 2003 |
CARCINOID SYNDROME ASSOCIATED WITH OAT-CELL CARCINOMA OF BRONCHUS.
Topics: Aprotinin; Aspirin; Avena; Bronchi; Bronchial Neoplasms; Carcinoma; Chlorpromazine; Drug Therapy; En | 1965 |
Treatment of multiple familial trichoepitheliomas with a combination of aspirin and a neutralizing antibody to tumor necrosis factor alpha: A case report and hypothesis of mechanism.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aspirin; Carcinoma; Di | 2006 |
Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers.
Topics: Animals; Aspirin; Carcinoma; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; | 2007 |
Aspirin versus colonoscopy in the reduction of carcinoma of the colon.
Topics: Adult; Aged; Aspirin; Carcinoma; Cohort Studies; Colonic Neoplasms; Colonoscopy; Humans; Male; Middl | 1995 |
Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines.
Topics: 3T3 Cells; Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Carcinoma; | 1996 |
Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Blood Pressu | 1999 |
Protein kinase C epsilon mediates the induction of P-glycoprotein in LNCaP prostate carcinoma cells.
Topics: Aspirin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Diterpenes; Enzyme Inhi | 2002 |
Initial tumor cell arrest in animals of defined coagulative status.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Carcinoma; Heparin; Lymphoma, Non-Hodgkin; Mice | 1978 |
Role of renal metabolism and excretion in 5-nitrofuran-induced uroepithelial cancer in the rat.
Topics: Administration, Oral; Animals; Aspirin; Carcinoma; FANFT; Glomerular Filtration Rate; In Vitro Techn | 1985 |
The management of upper gastro-intestinal tract haemorrhage.
Topics: Adolescent; Adult; Aged; Aortic Aneurysm; Aspirin; Carcinoma; Duodenal Ulcer; Esophageal and Gastric | 1973 |
Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease.
Topics: Adenocarcinoma; Animals; Aspirin; Blood Cell Count; Blood Platelets; Carcinoma; Cell Survival; Chrom | 1973 |